RhumbLine Advisers’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-334,270
| Closed | -$17.5M | – | 3080 |
|
|
2020
Q3 | $17.5M | Sell |
334,270
-32,180
| -9% | -$1.33M | 0.03% | 526 |
|
|
2020
Q2 | $12.2M | Buy |
366,450
+1,718
| +0.5% | +$54.7K | 0.02% | 672 |
|
|
2020
Q1 | $9.92M | Buy |
364,732
+25,392
| +7% | +$707K | 0.02% | 669 |
|
|
2019
Q4 | $6.7M | Buy |
339,340
+42,580
| +14% | +$681K | 0.01% | 1078 |
|
|
2019
Q3 | $3.85M | Buy |
296,760
+6,065
| +2% | +$73.2K | 0.01% | 1336 |
|
|
2019
Q2 | $3.62M | Buy |
290,695
+14,548
| +5% | +$193K | 0.01% | 1381 |
|
|
2019
Q1 | $4.01M | Buy |
276,147
+29,032
| +12% | +$371K | 0.01% | 1305 |
|
|
2018
Q4 | $2.73M | Buy |
247,115
+65,839
| +36% | +$916K | 0.01% | 1461 |
|
|
2018
Q3 | $4.77M | Sell |
181,276
-4,681
| -3% | -$127K | 0.01% | 1139 |
|
|
2018
Q2 | $3.8M | Buy |
185,957
+2,913
| +2% | +$62.5K | 0.01% | 1285 |
|
|
2018
Q1 | $3.32M | Buy |
183,044
+7,842
| +4% | +$131K | 0.01% | 1299 |
|
|
2017
Q4 | $2.44M | Buy |
175,202
+24,862
| +17% | +$336K | 0.01% | 1511 |
|
|
2017
Q3 | $2.78M | Buy |
150,340
+10,125
| +7% | +$169K | 0.01% | 1399 |
|
|
2017
Q2 | $2.37M | Buy |
140,215
+11,128
| +9% | +$169K | 0.01% | 1473 |
|
|
2017
Q1 | $1.72M | Buy |
129,087
+37,076
| +40% | +$581K | ﹤0.01% | 1641 |
|
|
2016
Q4 | $1.39M | Sell |
92,011
-5,371
| -6% | -$70.9K | ﹤0.01% | 1653 |
|
|
2016
Q3 | $1.14M | Buy |
97,382
+2,710
| +3% | +$31.9K | ﹤0.01% | 1739 |
|
|
2016
Q2 | $1.02M | Buy |
94,672
+17,864
| +23% | +$184K | ﹤0.01% | 1770 |
|
|
2016
Q1 | $710K | Buy |
76,808
+1,170
| +2% | +$12.6K | ﹤0.01% | 1996 |
|
|
2015
Q4 | $1.12M | Buy |
75,638
+6,835
| +10% | +$114K | ﹤0.01% | 1736 |
|
|
2015
Q3 | $1.13M | Buy |
68,803
+2,630
| +4% | +$53.8K | ﹤0.01% | 1694 |
|
|
2015
Q2 | $1.51M | Buy |
66,173
+9,495
| +17% | +$189K | ﹤0.01% | 1607 |
|
|
2015
Q1 | $862K | Buy |
56,678
+6,225
| +12% | +$80.9K | ﹤0.01% | 1953 |
|
|
2014
Q4 | $607K | Sell |
50,453
-1,025
| -2% | -$11.7K | ﹤0.01% | 2162 |
|
|
2014
Q3 | $584K | Sell |
51,478
-50
| -0.1% | -$570 | ﹤0.01% | 2111 |
|
|
2014
Q2 | $622K | Sell |
51,528
-3,908
| -7% | -$46.2K | ﹤0.01% | 2133 |
|
|
2014
Q1 | $646K | Sell |
55,436
-1,900
| -3% | -$32.2K | ﹤0.01% | 2054 |
|
|
2013
Q4 | $1.01M | Sell |
57,336
-1,280
| -2% | -$21.5K | ﹤0.01% | 1803 |
|
|
2013
Q3 | $843K | Sell |
58,616
-654
| -1% | -$10K | ﹤0.01% | 1888 |
|
|
2013
Q2 | $893K | Buy |
+59,270
| New | +$782K | ﹤0.01% | 1839 |
|
RhumbLine Advisers's MNTA Position: Q4 2020 in Review
RhumbLine Advisers sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 334,270 shares — an estimated $17.5M sold.
RhumbLine Advisers first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $17.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- RhumbLine Advisers reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- RhumbLine Advisers sold 334,270 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $17.5M.
- RhumbLine Advisers first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- RhumbLine Advisers's Momenta Pharmaceuticals, Inc. position peaked at $17.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.